0.40Open0.40Pre Close0 Volume22 Open Interest95.00Strike Price0.00Turnover37.54%IV15.47%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier30DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.0555Delta0.0092Gamma373.03Leverage Ratio-0.0214Theta-0.0048Rho-20.72Eff Leverage0.0363Vega
JM Smucker Stock Discussion
Chewy ( $Chewy (CHWY.US)$ ): Cramer praised Chewy's recent rebound and earnings growth, driven by positive trends in pet adoption.
Elanco ( $Elanco Animal Health (ELAN.US)$ ): A spin-off from Eli Lilly, Elanco has a promising pipeline, including treatments for canine parvovirus and diabetes in cats.
J.M. Smucker ( $JM Smucker (SJM.US)$ ): ...
My name is Kevin Travers. I am home sick today, but h...
$WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)
$PACB Barclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $3.00
$NFLX Netflix, Inc. (NASDAQ:NFLX) Receives $590.15 Consensus Target Price from Brokerages
$SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50
$RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00
$CERE Cerevel Thera...
Gapping up
$CVS Health (CVS.US)$ has forecasted revenue for 2024 to be at least $366 billion, which exceeds the current Street estimate of $345.5 billion. The company anticipates adjusted earnings per share of at least $8.50, in line with the consensus, with the cash flow from operations projected to be at least $12.5 billion. Updates were shared ahead of the company's 2023 Investor Day. CVS shares rose 2.2% on the ne...
No comment yet